Retina Associates, LLC: At the Forefront of Retinal Care
Our retina specialists advance and improve the treatment of diseases of the retina, macula, and vitreous through clinical studies, education, and the development of new instruments and techniques. Our physicians have participated in a multitude of retinal research studies and, in many, served as principal investigators or co-investigators. We proudly offer retinal clinical trials designed to enhance the vision, quality of life, and peace of mind of our patients.
Safely Advancing Quality of Care
Clinical trials involve scientific research into whether a new medication, device, or treatment strategy improves patient outcomes. Every treatment existing today has been through clinical trials. Not only do clinical trials help to develop new and improved treatment modalities, but they also connect patients with potentially vision-saving treatments before they’re available to the general public, which can make a huge difference for patients with severe or treatment-resistant cases.
You can be one of the first patients to benefit from a new medication or technique that goes on to be a respected and widely utilized standard of care. Furthermore, you can rest assured that our retina clinical trials adhere to the highest safety standards governed and reviewed by institutional review boards (IRBs).
Why Participate in a Retina-Related Clinical Trial?
Retina-related clinical trials allow participants to try new treatment methods that can slow the progression of eye-related diseases and improve vision outcomes. If your current treatment plan isn’t giving you optimal results, a retina clinical trial could offer a fresh new option.
Enroll in a Retina Associates Clinical Trial Today
Are you ready to be at the forefront of retina research and possibly improve your own vision and general well-being? Enroll in a clinical trial with the expert retina specialists at Retina Associates today. Review our upcoming studies below and contact us for more information.
Currently Enrolling
RGX-314 is being developed as a novel one-time gene therapy for the treatment of Neovascular Wet Age-Related Macular Degeneration as a potential one-time treatment for wet AMD.
RGX-314 is being developed as a novel one-time gene therapy for the treatment of Neovascular Wet Age-Related Macular Degeneration as a potential one-time treatment for wet AMD.
High Dose (8mg) Aflibercept for the treatment of Macular Edema secondary to Retina Vein Occlusion
Upcoming Studies:
A Study to Assess Safety and Efficacy of Multiple Doses of BI 771716 in Participants with Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Home Guided Treatment verus Treat and Extend for the Management of Neovascular Age-Related Macular Degeneration